MedTrace Logo

A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease

NCT01485965 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2013-03-20

No results posted yet for this study

Summary

The primary purpose of this study is to assess the effect of food upon the pharmacokinetics (PK) of SEN0014196 in subjects with Huntington disease (HD).

Conditions

Interventions

DRUG

SEN0014196

100 mg, immediate release tablets, once daily administration

Sponsors & Collaborators

  • Siena Biotech S.p.A.

    lead INDUSTRY

Principal Investigators

  • Francis O Walker, MD · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-11-30
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01485965 on ClinicalTrials.gov